Mereo BioPharma(MREO) - 2023 Q2 - Quarterly Report

Exhibit 99.1 MEREO BIOPHARMA GROUP PLC Condensed Consolidated Statements of Comprehensive Loss (unaudited) | | | Six months ended | Six months ended | | --- | --- | --- | --- | | | | June 30, | June 30, | | | | 2023 | 2022 | | | Notes | £'000 | £'000 | | Revenue | 3 | 7,128 | — | | Cost of revenue | 3 | (2,455) | 352 | | Research and development expenses | | (7,898) | (13,322) | | Administrative expenses | | (9,548) | (8,840) | | Other operating income | 3 | 2,864 | — | | Operating loss | | (9,909) | (21,81 ...